ArticleFrontiers in oncology2026

Modified systemic immune-inflammatory index, modified systemic inflammatory response index and hemoglobin-albumin-lymphocyte-platelet score may serve as markers for evaluating the efficacy of neoadjuvant therapy in breast cancer patients.

Yuhong Gan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.